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SummAry – The aim of this paper is to show the results of prostate cancer treatment in Prostate 
Center of department of urology at the university hospital Center zagreb. The answer to growing 
demands for prostate cancer treatment due to increasing incidence is the formation of specialized, 
multidisciplinary units/centers that deal mainly with prostate cancer. The need was recognized by 
european School of oncology and european Association of urology, who have proposed their con-
cepts of validating such centers with the aim of promoting high-quality prostate cancer treatment. 
following these trends, the department of urology at the university hospital Center zagreb has 
established the Prostate Center. This new unit offers specialized and individualized approach to work-
up, treatment and follow up for prostate cancer patients based on multidisciplinarity. The Prostate 
Center was also established as a platform for education and research.
key words: Prostate cancer; Cancer Care Facility; Patient Care Team; Urology; Medical Oncology; 
Radiation Oncology.
Correspondence to: Tomislav Kuliš, MD, PhD, FEBU, department 




incidence of prostate cancer has been increasing in 
europe during the last decades1 and it is now the most 
common cancer diagnosed in men2. despite the in-
crease in incidence, the mortality of prostate cancer 
has been decreasing in the developed countries of 
western europe3. Croatia’s prostate cancer incidence 
is also following global trends4 and, according to the 
last annual epidemiological report, in 2016 it has be-
come the most commonly diagnosed male cancer in 
Croatia5. on the other hand, prostate cancer mortality 
has an increasing trend3, 4. The reasons behind that 
could be socio-economic: the availability of the latest 
and most advanced diagnostic and therapeutic tools is 
reduced in developing countries. These countries are 
usually a few years behind in following trends that 
arise in developed countries. while some are tough to 
follow due to lack of financial abilities, some are mere-
ly organizational in nature and thus, easier to imple-
ment. multidisciplinarity is the key to successful can-
cer treatment6. following the results of the european 
breast cancer units that produced better outcomes in 
treatment of breast cancer in women, european School 
of oncology proposed formation of Prostate Cancer 
units (PCu) in 20117. After that, in 2012 a Prostate 
Cancer units initiative in europe was launched with a 
gathering of a multi-professional Task force to set 
standards for quality comprehensive prostate cancer 
care and designate care pathways in PCus8. following 
these trends and recommendations, in 2016 we have 
established a new organizational unit called The Pros-
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tate Center. The aim was to provide patients with dis-
eases of the prostate – prostate cancer, BPh and pros-
tatitis, a focused and specialized care based on indi-
vidual approach. Along with basic urologic workup for 
patients with luTS, its core functioning unit is mul-
tidisciplinary team (mdT) consisting of urologists, 
medical and radiation oncologists, radiologist and pa-
thologists. multidisciplinarity in cancer care is not 
new in our hospital since we have a 40-year long tradi-
tion of uro-oncological multidisciplinary team. for-
mation of the Prostate Center gave our team wider 
public recognition which increased the number of pa-
tients. Prostate Center encompasses the most impor-
tant elements of prostate cancer treatment. initial 
work-up is organized as an ambulatory care center 
where patients get the basic urologic workup with ba-
sic laboratory tests and urinalysis, PSA, uroflow, uri-
nary tract ultrasound, and urologic examination. in 
case of prostate cancer suspicion, prostate biopsy is 
performed. All biopsies are under the auspices of the 
Prostate Center, and in case of suspicious mri find-
ing, a targeted biopsy is performed. furthermore, once 
the diagnosis of prostate cancer is made, the decision-
making process of the best treatment modality is given 
by our multidisciplinary team for all newly diagnosed 
patients. Besides that, our mdT also plays a vital role 
during follow up in case of any recurrence and relapse. 
All patients that are diagnosed with prostate cancer in 
our institution must be presented to our multidisci-
plinary team. The added workload are also patients 
that are referred from other hospitals, usually smaller 
centers. The aim of this paper is to present the results 
of prostate cancer treatment in the Prostate Center.
Materials and Methods
A retrospective review of database of patients treat-
ed in the Prostate Center was performed. The data 
from medical history, biopsy, operative protocols and 
histopathological findings were analyzed. we also per-
formed an analysis of basic demographic, diagnostic 
and therapeutic data for patients with prostate cancer 
that were evaluated by our multidisciplinary team dur-
ing a one-year period in 2018. All the decisions re-
garding further diagnostic or therapeutic procedures 
Figure 1. Number of prostate biopsies, radical prostatectomies and patients at multidisciplinary prostate team  
during the last 5 years.
Figure 2. Proportion of Gleason scores for positive systematic and targeted biopsies.
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were divided into groups accordingly. results are pre-
sented using descriptive statistics.
Results
Since the establishment of the Prostate Center in 
december 2016, there were 2830 examinations which 
included male patients with luTS of any cause, but 
mostly BPh, prostatitis and prostate cancer. System-
atic biopsies are performed in the case of prostate can-
cer suspicion. Targeted biopsies are performed in case 
of prior negative biopsies and a multiparametric mri 
finding of PirAdS ≥3 lesion. The number of proce-
dures during the last five years has an increasing trend 
and is shown in figure 1. in 2018 there were 731 sys-
tematic and 67 targeted prostate biopsies. overall, 
prostate cancer was diagnosed in 45,1% of prostate 
biopsies. in case of patients with PSA for 4-10 ng/ml 
prostate cancer was diagnosed in 41,7% biopsies. The 
proportion of positive targeted biopsies is 65,7%. The 
mean age of patients that undergo prostate biopsy is 
67,7 (range 41-90 years of age). The median PSA value 
is 7,3 ng/ml (range 0,6-1269 ng/ml). The proportion 
of gleason scores for positive systematic and targeted 
biopsies is shown in figure 2. A more detailed analysis 
of radical prostatectomies was performed for year 2018 
and is presented in Table 1. A more detailed analysis of 
patients’ characteristics and treatment decisions was 
performed for 2018 and for newly diagnosed patients 
is shown in Table 2.
Discussion
formation of the Prostate Center at the depart-
ment of urology at the university hospital Center 
zagreb had a clear effect on the number of prostate 
cancer cases treated in our hospital. first the number 
of biopsies has almost doubled, and we started per-
forming targeted biopsies for patients with prior nega-
tive biopsies and prostate cancer suspicion. we per-
form cognitive fusion and our results of 65,7% positive 
findings are comparable to other series9. recently pub-
lished results of fuTure Trial showed that the tech-
nique of targeted biopsy doesn’t impact the outcomes10. 
even though cognitive fusion has a relatively short 
learning curve, still it requires a certain volume of pa-
tients. low volume centers are less likely to collect ad-
equate quantity of these procedures to justify routine 
performance.
Secondly, the number of radical prostatectomies 
has increased, nearly triple the number of procedures 
we performed five years ago. That is a direct effect of 
prostate biopsies increase and the number of patients 
that come to our multidisciplinary meetings from oth-
er hospitals. we have also recently started performing 
laparoscopic radical prostatectomies with 50 proce-
dures performed from february 2019. This reflects the 
most significant impact of the Prostate Center: impact 
on the quality of provided care to our patients. mod-
ern treatment and diagnostic workup of prostate can-
cer are rapidly progressing every year and it is hard to 
keep up with ever-changing guidelines. That is why it 
is of utmost importance to form such specialized cen-
ters where patients can be provided with the best of 













Table 2. Proportion of metastatic disease and treatment 
decision for newly diagnosed patients presented at 








Androgen deprivation therapy 7.6%
Further diagnostics 19.8%
T. Kuliš et al. Modern multidisciplinary prostate cancer care
Acta Clin Croat, Vol. 58, (Suppl. 2) 2019 19
care. in the last few years a lot of attention was given, 
and focus directed towards formation of such special-
ized prostate cancer centers throughout europe. first 
Prostate Cancer units emerged, and a certification 
process was proposed in order to improve standards of 
management of prostate cancer7. The authors proposed 
a set of minimum and mandatory requirements revolv-
ing around the volume of the center, data collection, 
core team, additional services personnel, multidisci-
plinary approach, availability of treatment options, or-
ganizational details and equipment. A project was es-
tablished that aims to develop the concept of “euro-
pean Prostate Cancer Centers of excellence“(ePPCe)11. 
These require four distinct steps for defining such a 
center of excellence: clinical step, research step, educa-
tional step and quality assurance/control procedures. 
The importance of Prostate Cancer units is also relat-
ed to a need for smaller, less equipped and staffed hos-
pitals which do not have the men power to provide 
patients with state-of-the-art prostate cancer care. it is 
their need for referral of such patients to Prostate 
Cancer units that also justifies their formation. in or-
der to treat patients better, there is a need to follow-up 
on results of treatment, data management and analysis. 
database buildup is paramount for quality assessment. 
Such centers must provide a broad spectrum of avail-
able diagnostic procedures including PeT CT with 
PSmA, multiparametric mri, fusion biopsies, etc. 
They must be able to provide a broad spectrum of 
treatment options including all forms of surgical man-
agement, radiotherapy, chemotherapy and androgen 
deprivation therapy. multimodality is the key to the 
best individualized treatment of prostate cancer pa-
tients. we must not forget the importance of such cen-
ters in education and research. with the establishment 
of a good prostate cancer patients’ database, regular 
follow-up and analysis of treatment results, they can 
form their own protocols and share experience through 
education of other urological and oncological special-
ists, residents and other medical personnel included 
in the care for prostate cancer patients. fulfilling the 
requirements is a plan for the future of the Prostate 
Center.
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Sažetak
CenTAr zA ProSTATu: mulTidiSCiPlinArnoST, orgAnizACiJA diJAgnoSTike  
i liJeČenJA rAkA ProSTATe
T. Kuliš, L. Penezić, M. Gamulin, I. Mokos, M. Marić, V. Ferenčak, E. Goluža, T. Hudolin i Ž. Kaštelan
Cilj ovog rada je prikazati rezultate liječenja pacijenata oboljelih od raka prostate u Centru za prostatu klinike za urolo-
giju kliničkog bolničkog centra zagreb. u svijetu i hrvatskoj incidencija raka prostate je u porastu zbog čega se javlja pove-
ćana potreba za liječenjem takvih pacijenata. Temeljem tih trendova započelo je stvaranje specijaliziranih, multidisciplinarnih 
timova koji se bave isključivo ovom bolešću. europska škola onkologije i europsko urološko društvo prepoznali su važnost 
tog koncepta te su ubrzo predstavili svoje kriterije vrednovanja i akreditiranja takvih centara kako bi se potaknulo podizanje 
kvalitete liječenja pacijenata s rakom prostate. klinika za urologiju kliničkog bolničkog centra zagreb je, potaknuta ovim 
trendovima, oformila Centar za prostatu koji pacijentima s rakom prostate nudi specijalizirani i individualizirani pristup 
dijagnostici, liječenju i praćenju utemeljen na multidisciplinarnosti. Centar za prostatu je također osmišljen i kao platforma 
za edukaciju i znanstvena istraživanja.
ključne riječi: Rak prostate; Jedinica za liječenje raka; Timsko liječenje bolesnika; Urologija; Internistička onkologija; Radijacij-
ska onkologija
